Amanda Hempel Zinglersen

Amanda Hempel Zinglersen

Auto-generated profile, based on publicly available information

Amanda Hempel Zinglersen

Copenhagen Research Center for Autoimmune Connective Tissue Diseases (COPEACT), Copenhagen University Hospital, Rigshospitalet, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
AZAmanda Hempel Zinglersen
Amanda Hempel Zinglersen
KIKatrine Kjær Iversen
Katrine Kjær Iversen
HLHenrik Christian Bidstrup Christian Bidstrup Leffers
Henrik Christian Bidstrup Christian Bidstrup Leffers
ELEsben Laugesen
Esben Laugesen
JFJesper Fleischer
Jesper Fleischer
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Objectives Cardiovascular autonomic neuropathy (CAN) may affect the clinical course of SLE leading to reduced quality of life. CAN is assessed by heart rate variability (HRV) measures and cardiovascular autonomic reflex tests (CARTs). In patients with SLE, we aimed to determine the characteristics of CAN and if CAN associates with health-related quality of life (HRQoL). Methods Patients with SLE and healthy controls (HCs) were CAN tested with 5 min HRV and three CARTs to determine parameters reflecting parasympathetic and mixed sympathetic–parasympathetic function. Subjects were classified as having no, early or definitive CAN by having none, one or more than one abnormal CART, respectively. HRQoL as determined by the Short Form 12 (SF-12) was assessed in SLE. Results Of 111 patients with SLE, 92 answered the SF-12 and 54 were matched with 54 HCs for characterisation of CAN. Definitive CAN was present in 24.1% (95% CI 15% to 37%) patients with SLE and 1.9% (95% CI 0.3% to 9.8%) HCs (OR 16.8, 95% CI 2.1 to 133.8, p=0.008). The corresponding prevalences of any CAN were 53.7% (95% CI 41% to 66%) and 22.6% (95% CI 13% to 35%). SLE patients with definitive CAN showed signs of mixed sympathetic–parasympathetic dysfunction, whereas patients without CAN primarily presented with impaired parasympathetic activity. Signs of parasympathetic as well as sympathetic–parasympathetic dysfunction were associated with low physical SF-12 component score (all: β>0.211, p<0.05). The mental SF-12 component score was not associated with any CAN indices. Conclusions CAN was a frequent finding in SLE and associated to self-report on impaired physical HRQoL. Even patients without CAN showed signs of impaired parasympathetic function compared with controls.

13 January 2025 in Rheumatology International
Verified
Journal Article
Open access
PDF file
LZLise Zinglersen
Lise Zinglersen
AZAmanda Hempel Zinglersen
Amanda Hempel Zinglersen
KMKatrine Aagaard Myhr
Katrine Aagaard Myhr
MHMarie-Louise Hermansen
Marie-Louise Hermansen
KKKlaus Fuglsang Kofoed
Klaus Fuglsang Kofoed
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
To investigate if progression of coronary artery calcification (CAC) in patients with systemic lupus erythematosus (SLE) is associated with renal and traditional cardiovascular risk factors as well as incidence of myocardial infarctions. CAC progression was evaluated by cardiac computed tomography (CT) at baseline and after 5 years. Multivariable Poisson regression was applied to investigate associations between CAC progression and baseline values for traditional cardiovascular risk factors, CAC, SLE disease duration, lupus nephritis, and renal function. Regarding renal function, three groups were defined based on eGFR. Further, we analysed association between CAC progression and myocardial infarction during follow-up. Of the 147 SLE patients, 99 had cardiac CT at baseline and 5-year follow-up, with a total of 502 patient-years. At baseline, their median age was 47 years, median SLE disease duration was 14 years, 88% were women, 58% had lupus nephritis, and the median eGFR was 99 mL/min/1.73m2. 38/99 (39%) had CAC progression. CAC progression was associated with smoking (ever) (relative risk [RR] 1.69, CI95% 1.19–2.40), SLE disease duration (RR per year 1.03, CI95% 1.01–1.04), and CAC presence (RR 2.52, CI95% 1.68–3.78) at baseline. During follow-up, myocardial infarction occurred in three (7.9%) CAC progressors and in two (3.3%) patients who did not have CAC at any time (RR 2.1, CI95% 0.0-5.5). In this study, progression of CAC was associated with smoking, SLE disease duration and the prior presence of CAC, but it was inconclusive as to associations with renal involvement and incidence of MI.

9 October 2023 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
KMKatrine A. Myhr
Katrine A. Myhr
AZAmanda H. Zinglersen
Amanda H. Zinglersen
RPRedi Pecini
Redi Pecini
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that carries increased risk of cardiovascular disease; however, the underlying pathophysiological mechanisms remain poorly understood. We aimed to investigate the prevalence and degree of myocardial fibrosis in SLE patients and associated disease characteristics. Forty-nine SLE patients (89% female, mean age 52 ± 13 years, median disease duration 19 (11–25) years) and 79 sex-and age-matched healthy controls were included. CMR with T1 mapping was performed on SLE patients and healthy controls. Fifty-one SLE patients received gadolinium contrast for the evaluation of late gadolinium enhancement (LGE) and extra cellular volume (ECV). Multiple linear regression analyses were performed to investigate the association between markers of myocardial fibrosis on CMR (LGE, T1, ECV) and SLE-related variables [clinical disease activity, lupus nephritis, chronic kidney disease, anti-cardiolipin and/or anti-beta-2 glycoprotein I antibodies, and lupus anticoagulant (LAC)] with adjustment for traditional risk factors. T1 values were elevated in SLE patients compared to healthy controls (1031 ± 36 ms vs. 1019 ± 25 ms, p = 0.01). LGE was present in 20% of SLE patients who received gadolinium contrast. On multivariable analysis, LAC was associated with LGE in SLE patients (β = 3.87, p = 0.02). Neither T1 nor ECV associated with SLE disease characteristics; however, there was a trend towards an association between LAC and T1 (β = 16.9, p = 0.08). SLE patients displayed signs of myocardial fibrosis on CMR that were associated with the presence of LAC. These findings support the pathophysiological understanding of LAC as a mediator of microvascular and subsequent myocardial dysfunction. Graphical abstract

20 September 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
AZAmanda Hempel Zinglersen
Amanda Hempel Zinglersen
IDIda Lynghøj Drange
Ida Lynghøj Drange
KMKatrine Aagaard Myhr
Katrine Aagaard Myhr
AFAndreas Fuchs
Andreas Fuchs
MPMogens Pfeiffer-Jensen
Mogens Pfeiffer-Jensen
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Introduction Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE is treated with immunosuppressants with suboptimal efficacy and high risk of serious side effects. Patients with SLE have increased risk of mortality, organ damage and debilitating treatment-resistant fatigue. Autonomic nervous system dysfunction (AD) is present in approximately half of the patients and may promote autoimmunity by weakening the vagally mediated anti-inflammatory reflex. Recent studies suggest that transcutaneous vagus nerve stimulation (tVNS) has few side effects and beneficial effects on fatigue, pain, disease activity and organ function. This study investigates whether adjuvant tVNS improves measures of fatigue (primary end point), AD, clinical disease activity, inflammation, pain, organ function and quality of life. Hence, this study will contribute to the understanding of AD as a potentially important precursor of fatigue, disease activity, progression and complications in SLE, and how tVNS mechanistically may attenuate this. As adjuvant tVNS use may reduce the need for traditional immunosuppressive therapy, this trial may prompt a shift in the treatment of SLE and potentially other autoimmune disorders. Methods and analysis Eighty-four patients with SLE with fatigue and AD will be randomised 1:1 to active or sham tVNS in this double-blinded parallel-group study. In period 1 (1 week), participants will receive a 4 min tVNS 4 times daily and report on fatigue daily. After a 2-week pause, period 2 (8 weeks) will entail tVNS twice daily and participants will report on fatigue, pain and disease activity weekly. Secondary end points will be assessed before and after each period and after 1 week in period 2. Ethics and dissemination The study is approved by the Danish Medical Research Ethical Committees (case no: 2120231) and results will be published in international peer-reviewed journals. Trial registration number NCT05315739.

24 August 2022 in Journal of Autoimmunity
Verified
Journal Article
Open access
KMKatrine A. Myhr
Katrine A. Myhr
AZAmanda H. Zinglersen
Amanda H. Zinglersen
MHMarie-Louise F. Hermansen
Marie-Louise F. Hermansen
MJMathies M. Jepsen
Mathies M. Jepsen
KIKatrine K. Iversen
Katrine K. Iversen
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with increased risk of cardiac dysfunction. The pathophysiological mechanisms are poorly understood, and prognostic markers are warranted. Purpose: We aimed to identify SLE-characteristics associated with measures of cardiac size and function during a five-year follow-up. Methods: We included 108 patients with SLE: 90% females, mean age 46 +/- 13 years, median disease duration 14 (range 7-21) years. We performed blood sampling for potential biomarkers as well as a standard echocardiography at baseline and at a 5-year follow-up. To investigate associations with baseline and prospective 5-year changes in echocardiographic parameters, we performed multivariate regression analyses of SLE-related base-line variables (clinical disease activity, lupus nephritis, chronic kidney disease, anti-cardiolipin and/or anti-beta -2 glycoprotein I antibodies, and lupus anticoagulant (LAC)) and adjusted for traditional risk factors. Results: During follow-up, diastolic function regressed in two out of five echocardiographic measures (E/A ratio 1.4 +/- 0.5 vs. 1.3 +/- 0.5, p = 0.002; tricuspid regurgitation peak velocity 2.0 +/- 0.6 vs. 2.2 +/- 0.4 mmHg, p < 0.001). Left ventricular (LV) end-diastolic volume index increased (43.7 +/- 13.9 vs. 52.5 +/- 15.7 mL/m2, p < 0.001). Left and right ventricular systolic function remained stationary. LAC was associated with inferior diastolic function: lower E/A ratio (p = 0.04) and higher E/e' ratio at baseline (p = 0.04) and increased left ventricular atrial volume index during follow-up (p = 0.01). LAC was further associated with LV dilatation during follow-up (p = 0.01). Conclusion: Presence of LAC was associated with measures of diastolic function as well as progressive LV dilatation during the 5-year follow-up. Thus, LAC might be a predictor of cardiac dysfunction in SLE patients. LAC is known to have implications for the microvascular circulation, but the clinical significance of the present findings is yet to be elucidated.

23 March 2020
Verified
Conference Paper
Open access
PDF file
AZAmanda Zinglersen
Amanda Zinglersen
KIKatrine Iversen
Katrine Iversen
ELEsben Laugesen
Esben Laugesen
JFJesper Fleischer
Jesper Fleischer
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Background The prevalence of cardiovascular autonomic dysfunction (CAN) has previously been described with large variation (10–90%) in patients with systemic lupus erythematosus (SLE). CAN is assessed by heart rate variability (HRV) or cardiovascular autonomic reflex tests (CARTs), but these two methods have not previously been compared in SLE patients. Further, little is known about the autonomic nervous system (ANS) impairments at different stages of CAN. Consequently, the purpose of this study is, in a large cohort of SLE patients, to determine the prevalence of CAN and to characterize the ANS function at different CAN-stages by HRV and CARTs. Methods CAN was tested in 111 SLE patients with a 5-minute HRV-test and three CARTs. HRV-items reflecting parasympathetic (PNS) function (high frequency power, HFP) and mixed PNS-sympathetic (SNS) function (low frequency power, LFP; total power, TP; LFP/HFP-ratio and peak LF) were calculated. CAN was staged by the number of abnormal CARTs; early CAN: one abnormal CART, definite CAN: two or more abnormal CARTs. Fifty-five SLE patients were age and gender matched to 55 CAN-tested healthy controls (HC). Results The prevalence of definite CAN in SLE is higher than in HCs (24.1% vs. 1.9%, p=0.001). CAN-stage was significantly associated all HRV-measures, except LF/HF-ratio. SLE patients without definite CAN had lower PNS activity than HCs without definite CAN (HFP: 42.7 vs. 87.5 ms2, p=0.006; LFP/HFP-ratio: 1.79 vs. 1.00, p=0.010, resp.). Furthermore, SLE patients with definite CAN had signs of lower mixed PNS-SNS-function as determined by LFP, TP and peak LF (all p<0.05), see table 1. Measures of heart rate variability (HRV) by cardiovascular autonomic neuropathy (CAN) (-CAN = no and early CAN +CAN = definitive CAN) for age and gender matched systemic lupus erythematosus (SLE) patients and healthy controls (HC) Conclusions The prevalence of CAN in SLE patients was 12 times higher than in HCs. In SLE patients, early CAN was associated with impaired PNS function, whereas definite CAN was characterized by impaired function of the PNS and SNS.